Vistagen to participate in stifel 2025 virtual cns forum

South san francisco, calif.--(business wire)--vistagen (nasdaq: vtgn), a clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced that management will participate in stifel's 2025 virtual cns forum. vistagen's president and chief executive officer, shawn singh, will participate in a fireside chat presentation on tuesday, march 18, 2025, at 12 p.m.
VTGN Ratings Summary
VTGN Quant Ranking